BerganKDV Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

BerganKDV Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2	Closed	-$401	–	872
2023 Q1	$401	Sell	2 -2	-50%	-$420	﹤0.01%	990
2022 Q4	$951	Buy	4 +2	+100%	+$427	﹤0.01%	886
2022 Q3	$0	Hold	2	–	–	﹤0.01%	960
2022 Q2	$0	Hold	2	–	–	﹤0.01%	966
2022 Q1	$0	Hold	2	–	–	﹤0.01%	991
2021 Q4	$0	Hold	2	–	–	﹤0.01%	1048
2021 Q3	$0	Hold	2	–	–	﹤0.01%	1030
2021 Q2	$0	Buy	+2	New	+$293	﹤0.01%	979
2020 Q3	–	Sell	-19	Closed	-$3K	–	907
2020 Q2	$3K	Buy	+19	New	+$2.56K	﹤0.01%	682

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BerganKDV Wealth Management's ALNY Position: Q2 2023 in Review

BerganKDV Wealth Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2023, closing a stake of 2 shares — an estimated $401 sold.

BerganKDV Wealth Management first reported a position in ALNY in Q2 2020 and held it in 9 quarters. The position peaked at $3K in Q2 2020. 476 funds tracked by Wall St. Rank hold ALNY as of Q2 2023.

BerganKDV Wealth Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
BerganKDV Wealth Management sold 2 Alnylam Pharmaceuticals shares in Q2 2023, an estimated $401.
BerganKDV Wealth Management first reported a position in Alnylam Pharmaceuticals in Q2 2020 and held it in 9 quarters.
BerganKDV Wealth Management's Alnylam Pharmaceuticals position peaked at $3K in Q2 2020.
476 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2023.

Based on BerganKDV Wealth Management's 13F filing for Q2 2023, filed 24 Jul 2023.